I am excited to join the BEVC advisory team and to help aspiring academic entrepreneurs translate their scientific discoveries to products that benefit society through improving human health. UC Berkeley has a vibrant ecosystem that brings diverse scientists, engineers, physicians, and business experts together to advance this cause, which I benefited from myself as a former Cal PhD student and faculty member.
Carolyn Bertozzi, Ph.D. is the Anne T. and Robert M. Bass Professor of Chemistry and, by courtesy, Professor of Chemical & Systems Biology and Radiology at Stanford University, the Director of Stanford’s Sarafan ChEM-H Institute, and an Investigator of the Howard Hughes Medical Institute. In 2022, Professor Bertozzi received the Nobel Prize in Chemistry for founding the field of bioorthogonal chemistry, a set of chemical reactions that allow researchers to study molecules and their interactions in living systems without interfering with natural biological processes. Professor Bertozzi has co-founded 14 companies advancing her work and other approaches for therapeutic application and has previously served on the scientific advisory boards for GlaxoSmithKline and several other biotech companies. She currently serves on the Board of Directors for Alnylam Pharmaceuticals, OmniAb and Xaira Therapeutics, and previously served on Eli Lilly and Company’s Board of Directors from 2017 to 2021. Professor Bertozzi is an elected member of the National Academy of Medicine, National Academy of Sciences, National Academy of Engineering, and the American Academy of Arts and Sciences and has been awarded the Welch Award, the Wolf Prize in Chemistry, the Heineken Prize, the Solvay Prize in Chemistry, the Lemelson-MIT Prize, and a MacArthur Foundation Fellowship, among many others. She completed her B.S. in Chemistry from Harvard University and her Ph.D. in Chemistry from the University of California, Berkeley.
